On 5 June 2025, the Annual General Meeting of Arco Vara AS adopted the decision to issue a targeted share offering to specific investors in order to increase the company’s share capital.Arco Vara AS announces that the targeted share issue approved by the shareholders has been successfully completed as of 11 June 2025 – the management board has adopted a resolution to shorten the subscription period due to early subscription of issued shares. In accordance with the adopted decision of the general meeting: Th ...

LONDON, June 12, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, today announces updated long term data (up to approximately three years of follow up) from the FELIX study of obecabtagene autoleucel (obe-cel) in adult patients with relapsed/refractory (r/r) B-cell acute lymphoblastic leukemia (B-ALL), to be presented in an oral presentation at the Europe ...

PRESS RELEASE In addition to patent protection, AB8939 is also eligible for regulatory data protection in Canada, preventing generic competition for a period of 8 years following initial approval. AB8939 has also received orphan drug designation for AML from both the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA). This orphan drug designation provides 10 and 7 years of market exclusivity in Europe and the United States, respectively, after product approval. A separate secondar ...

The deal was inked more than a year ago. Liberty Media (NASDAQ: FWONA )(NASDAQ: FWONK ) agreed to acquire 86% of Dorna (the commercial rights holder of MotoGP) for EUR 3.0B (equity portion, to be funded mostly in cash). Initially, EU competition regulators appeared concerned. AfterStriving to compound knowledge. Long-time fan of Warren and Charlie. Always invert. "To finish first, you must first finish". Investing own and family funds for +20 years. Senior finance roles at public and private corporations fo ...

SAN DIEGO, June 12, 2025 /PRNewswire/ -- Robbins LLP informs stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Rocket Pharmaceuticals, Inc. (NYSE: RCKT) securities between February 7, 2025 and May 26, 2025. Rocket is a fully integrated, late-stage biotechnology company focused on the development of gene therapies, with direct on-target mechanism of action and clear clinical endpoints, for rare and devastating diseases.For more information, submit a form, e ...

Lockheed Martin shares dropped as much as 7% on Wednesday after news that the Pentagon is asking for half of the F-35s it initially forecast for the Air Force. The defense contractor's shares recovered to $456 at market close, or about 4.2% lower from $476, the price at the end of Tuesday's trading day.Bloomberg reported on Wednesday that a procurement document sent to Congress indicated the Defense Department is requesting only 24 F-35 Lightning II Joint Strike Fighters for the Air Force, down from 48 tha ...

Utrecht, 12 June 2025 Aalberts announces the successful signing and closing of Note Purchase Agreements for its inaugural debt issuance in the US Private Placement (USPP) market, securing a total equivalent amount of approximately USD 600 million. The transaction comprises approximately USD 500 million and EUR 100 million in Senior Notes, with maturities ranging from 5 to 12 years. Funding has been completed early June. This landmark issuance earmarks a significant milestone in the further optimisation of A ...

Berry Corporation (NASDAQ: BRY ) recently reported a large impairment, which caused a large decrease in the total net income. Considering that the impairment is an extraordinary event, in my view, in the coming years, we will most like to see net income growth without newBased in Europe, I am an independent investor with more than a decade of experience. I research cash flow statements and unlevered free cash flow figures. My articles may include a number of assumptions about the future free cash flow of co ...

Core Insights - The Phase 3 PHOENYCS GO study results indicate that dapirolizumab pegol (DZP) shows significant clinical improvements in disease activity for patients with moderate-to-severe systemic lupus erythematosus (SLE) [1][4][6] - The study demonstrated improvements in fatigue and disease activity measures, suggesting DZP's potential as a new treatment option for SLE [2][3][5] Company Overview - UCB is a global biopharmaceutical company focused on innovative medicines for severe diseases of the immune system and central nervous system, generating €6.1 billion in revenue in 2024 [13] - Biogen is a leading biotechnology company that develops innovative therapies, leveraging deep biological understanding to create new medicines [14] Clinical Study Findings - At Week 48, 40.9% of participants receiving DZP achieved low disease activity compared to 19.6% in the standard of care (SOC) group, with significant differences noted as early as Week 12 [6][7] - Improvements in fatigue were quantified, with the DZP group showing a change from baseline of 8.9 in FACIT-Fatigue scores versus 5.2 in SOC alone [5] - The safety profile of DZP was generally favorable, with treatment-emergent adverse events (TEAEs) occurring in 82.6% of DZP participants compared to 75.0% in SOC [8] Future Developments - A second Phase 3 trial, PHOENYCS FLY, is ongoing to further confirm the efficacy and safety of dapirolizumab pegol in SLE [9]

SIKA IS UNLOCKING SMART AND DURABLE SOLUTIONS FOR DATA CENTER CONSTRUCTIONToday in Dallas, United States, Sika outlines strategic initiatives and high-performance solutions that will drive the future of data center construction. With over 1,000 data centers built using Sika solutions and a strong pipeline of new projects, Sika has become the trusted partner of technology leaders shaping digital infrastructure worldwide. Global investments in data centers are projected to exceed CHF 400 billion by 20281, dri ...